Clinical trials: Cancer Pediatric
Bloodstream Infection
Next Generation Pathogen Sequencing for Prediction of Adverse Events
The majority of children and adolescents diagnosed with cancer will experience one or more episodes of fever or infection during their course of therapy.
- Trial name
- NCT03226158
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- St. Jude Children's Research Hospital
Pediatric Solid Tumor
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors
Irinotecan is a commonly used salvage chemotherapy drug for children with relapsed and refractory solid tumors. Common dose-limiting toxicities of irinotecan include abdominal pain and diarrhea.
- Trial name
- NCT06760117
- Testing
- Irinotecan (CPT-11), Temozolomide (TMZ), Vincristine
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Neuroblastoma (NBL), Ewing Sarcoma
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
This study will test a CAR T-cell treatment combined with bevacizumab in children and young adults with relapsed or refractory neuroblastoma, Ewing sarcoma, or osteosarcoma.
- Conditions
- Neuroblastoma (NBL), Ewing Sarcoma, Osteosarcoma
- Trial name
- GD2CART-BEV (NCT07897968)
- Testing
- Chimeric Antigen Receptor (CAR) Therapy Infusion, Bevacizumab (Avastin)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Universität Münster
Leukemia, B-cell, Lymphoma, B-Cell
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
This study combines the immune checkpoint inhibitor pembrolizumab with the BITE antibody blinatumomab for the treatment of relapsed/refractory pre-B cell ALL.
- Trial name
- NCT03605589
- Testing
- Blinatumomab, Pembrolizumab
- Where
- United States
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
This study will assess the pharmacokinetics of imatinib in pediatric patients ages 1 to <4 years of age to help develop dosing regimens
- Conditions
- Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL), Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)
- Trial name
- NCT01066468
- Testing
- Gleevec/Glivec
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may make the tumor cells more sensitive to radiation therapy.
- Conditions
- Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma
- Trial name
- NCT00042991
- Testing
- gefitinib, radiation therapy, pharmacological study
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Epstein-Barr Virus Infection, Cytomegalovirus Infections
TETRAVI Expanded Access Program
This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the…
- Conditions
- Epstein-Barr Virus Infection, Cytomegalovirus Infections, Adenovirus Infection, BK Virus Infection
- Trial name
- NCT07104591
- Testing
- HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes)
- Sponsor
- Baylor College of Medicine
Osteosarcoma, Ewing's Sarcoma
Informed Consent in Pediatric Cancer Trials
Background: Informed consent is the process by which prospective participants in clinical trials learn about clinical research in order to decide whether they want to enroll in the study.
- Conditions
- Osteosarcoma, Ewing's Sarcoma, Neuroblastoma, Brain Tumors
- Trial name
- NCT00923650
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
This study will be conducted to evaluate the safety, pharmacokinetics (PK), and efficacy of adjunctive GWP42003-P in participants < 2 years of age with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome (LGS), or Dravet…
- Conditions
- Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
- Trial name
- NCT04485104
- Testing
- GWP42003-P
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 3 people
- Sponsor
- Jazz Pharmaceuticals
Central Nervous System Tumor, Pediatric
The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors
Surgery is the cornerstone treatment of most pediatric CNS tumors, including astrocytomas, ependymomas, medulloblastomas, and many other pathologies.
- Trial name
- 5-ALA (NCT02050243)
- Testing
- 5ALA
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Pediatric Cancer
Virtual Reality on Pain, Fear and Emotional Experience During Port Needle Insertion
In pediatric hematology-oncology patients, the need for a central venous catheter may arise in some cases to provide treatment. Totally implanted vascular access devices are known as "ports," and port catheters are commonly used…
- Trial name
- NCT06605339
- Testing
- Virtual Reality
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Dokuz Eylul University
Ewing Sarcoma, Rhabdomyosarcoma
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
The PerVision trial utilizes an approach of a patient-individual cancer vaccine with sarcoma-specific peptides in metastasized fusion-driven sarcoma patients determined by next generation whole exome sequencing of tumor and…
- Conditions
- Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma
- Trial name
- PerVision (NCT06094101)
- Testing
- Peptide vaccine IPX
- Where
- 4 sites in Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Tuebingen
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
This study is a Phase III, randomized, open-label, multi-center, prospective study of single umbilical cord blood (UCB) transplantation versus double UCB transplantation in pediatric patients with hematologic malignancies.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00412360
- Testing
- Single Umbilical Cord Blood Unit Transplant, Double Umbilical Cord Blood Unit Transplant, Total Body Irradiation
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 224 people
- Sponsor
- Medical College of Wisconsin
Liver Cancer
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
This study enrolls patients who have GPC3-positive solid tumors currently. Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment.
- Trial name
- GAP (NCT02932956)
- Testing
- GAP T cells, Cytoxan, Fludara
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor College of Medicine
Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN)
Phase II Study of QLC2519 in Pediatric Solid Tumor Participants
QLC2519 (Mai Li Sheng®) is a new protein drug created by fusing the N-terminal of highly active modified G-CSF with the C-terminal of HSA.
- Conditions
- Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN), Neutropenia
- Trial name
- NCT07724756
- Testing
- Albipagrastim alf
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Pediatric Cancer
CanMove: A Physical Activity Program for Children With Cancer
This study will evaluate a physical activity intervention for children during acute cancer treatment. The intervention aims to encourage children to participate in increased levels of physical activity and reduce the amount of…
- Trial name
- NCT04483362
- Testing
- Complex physical activity intervention
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- Murdoch Childrens Research Institute
Parents, Oncology
Effect of Individualized Nursing Care for Parents of Pediatric Oncology Patients
Objective: This study was planned to evaluate the effectiveness of individualized nursing care based on the Professional Values Model for parents of pediatric oncology patients.
- Trial name
- NCT05191641
- Testing
- Individualized nursing care
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Akdeniz University
Central Nervous System Neoplasm, Infantile Fibrosarcoma
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back.
- Conditions
- Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia
- Trial name
- NCT03834961
- Testing
- Larotrectinib Sulfate
- Where
- 80 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- Children's Oncology Group
Hodgkin Lymphoma
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
This phase II trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with favorable-risk Hodgkin lymphoma.
- Trial name
- NCT00846742
- Testing
- Stanford V Chemotherapy, Radiation Therapy
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
This is a prospective, single-center, single-arm interventional trial conducted at Tianjin Medical University Cancer Institute and Hospital.
- Trial name
- NCT07444918
- Testing
- Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.